Altimmune reports Q1 net loss $20.1M; pemvidutide NASH trial initiation mid-2023

Altimmune, Inc.

2023-Q1 EPS reported -$0.39 revenue$21,000

Net loss of $20.1M ($0.40/share) vs $19.4M ($0.44/share) in Q1 2022; R&D expenses $17.2M.
Cash $165.8M at March 31, 2023; MOMENTUM obesity trial 48-week top-line results expected Q4 2023.
Pemvidutide 24-week data: 10.7% (2.4mg) and 9.4% (1.8mg) mean weight loss; ~50% achieved ≥10% loss.
IMPACT Phase 2b NASH trial (~190 subjects) to start mid-2023; top-line results expected Q1 2025.
HepTcell Phase 2 CHB trial fully enrolled (~80 subjects); top-line results expected Q1 2024.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Altimmune, Inc. reported three months ended March 31, 2023 results: net income $20.1 million, EPS $0.40 net loss per share.

Period: three months ended March 31, 2023
Net income: $20.1 million
EPS: $0.40 net loss per share
Result: reported results

Exact text from the filing

Net loss for the three months ended March 31, 2023 was $20.1 million, or $0.40 net loss per share, compared to a net loss of $19.4 million, or $0.44 net loss per share, in the same period in 2022.

View on SEC.gov

36 earnings releases filed in the last 30 days. Browse all earnings releases →

Altimmune, Inc. filing history →

Source: SEC EDGAR

accession 0001326190-23-000025

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.